Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Concarlo: targeting proliferation and resistance in one go

SUNY Downstate spinout takes aim at metastatic breast cancer by targeting p27

By Virginia Li, Associate Editor
August 28, 2020 9:42 PM UTC

Concarlo is developing targeted therapies for metastatic breast cancer that take aim at both CDK4/6-driven cell proliferation and CDK2-driven drug resistance in one go. 

The company spun out of SUNY Downstate Medical Center, where Concarlo Holdings LLC co-founder and CEO Stacy Blain is an associate professor of pediatrics and cell biology...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article